RT Journal Article
SR Electronic
T1 The Dynamic Changes of Antibodies against SARS-CoV-2 during the Infection and Recovery of COVID-19
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2020.05.18.20105155
DO 10.1101/2020.05.18.20105155
A1 Li, Kening
A1 Wu, Min
A1 Huang, Bin
A1 Zhong, Aifang
A1 Li, Lu
A1 Cai, Yun
A1 Wu, Lingxiang
A1 Zhu, Mengyan
A1 Li, Jie
A1 Wang, Ziyu
A1 Wu, Wei
A1 Li, Wanlin
A1 Bosco, Bakwatanisa
A1 Gan, Zhenhua
A1 Wang, Zhihua
A1 Qiao, Qinghua
A1 Wu, Jian
A1 Wang, Qianghu
A1 Wang, Shukui
A1 Xia, Xinyi
YR 2020
UL http://medrxiv.org/content/early/2020/05/21/2020.05.18.20105155.abstract
AB Deciphering the dynamic changes of antibodies against SARS-CoV-2 is essential for understanding the immune response in COVID-19 patients. By comprehensively analyzing the laboratory findings of 1,850 patients, we describe the dynamic changes of the total antibody, spike protein (S)-, receptor-binding domain (RBD)-, and nucleoprotein (N)- specific IgM and IgG levels during SARS-CoV-2 infection and recovery. Our results indicate that the S-, RBD-, and N- specific IgG generation of severe/critical COVID-19 patients is one week later than mild/moderate cases, while the levels of these antibodies are 1.5-fold higher in severe/critical patients during hospitalization (P<0.01). The decrease of these IgG levels indicates the poor outcome of severe/critical patients. The RBD- and S-specific IgG levels are 2-fold higher in virus-free patients (P<0.05). Notably, we found that the patients who got re-infected had a low level of protective antibody on discharge. Therefore, our evidence proves that the dynamic changes of antibodies could provide an important reference for diagnosis, monitoring, and treatment, and shed new light on the precise management of COVID-19.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis study was supported by the National Natural Science Foundation of China (Grant Nos. 81572893, 81972358, 81959113), Key Foundation of Wuhan Huoshenshan Hospital (Grant No. 2020[18]), Key Research & Development Program of Jiangsu Province (Grant Nos. BE2017733, BE2018713), Medical Innovation Project of Logistics Service (Grant No. 18JS005), Basic Research Program of Jiangsu Province (Grant No. BK20180036).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll the data supporting the findings of this study are available within the article and its Supplementary information files and from the corresponding author upon reasonable request. A reporting summary for this article is available as a Supplementary information file.